Sorry, you need to enable JavaScript to visit this website.
Skip to main content


Primary IgA Nephropathy is a chronic autoimmune disease4-6

IgA Nephropathy is the most common cause of the primary glomerular diseases that can lead to end-stage renal disease (ESRD).6

global pointers

~2.5/ 100,000

individuals per year suffer from IgAN worldwide7


Half of patients with IgA Nephropathy may progress to ESRD within 20 years2,3

IgA Nephropathy is often asymptomatic in early stages. Patients may go undiagnosed until a decline in kidney function has already occurred6,10


IgA Nephropathy progression comes at a high cost.11


According to the American Journal of Managed Care, mean annual costs for patients with ESRD were $121,948 for commercial groups and $87,339 for Medicare groups12


Progressive IgA Nephropathy can also have a deep impact on emotional and psychosocial aspects, as well as a patient’s ability to perform physical activities6


In the American Journal of Kidney Diseases, the mortality rate in patients with moderate- or high-risk IgAN was twice that of the general population in a large cohort study (N=665) followed for a mean duration of 11.8 years (range: 0.0 to 20.8 years)13

Learn about the autoimmune effect in IgAN disease


Sign up to be the first to receive all the latest IgA Nephropathy news and updates

Stay connected with Calliditas.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
One or more fields have an error. Please check and try again.

IgA=immunoglobulin A; IgAN=immunoglobulin A Nephropathy; MOD=mechanism of disease.

References: 1. Barratt J, Rovin BH, Cattran D, et al. Kidney Int Rep. 2020;5(20):1620-1624. doi:10.1016/j.ekir.2020.08.009

2. Hastings MC, Bursac Z, Julian BA, et al. Kidney Int Rep. 2017;3(1):99-104. doi:10.1016/j.ekir.2017.08.008

3. Schena FP. Am J Med. 1990;89(2):209-215. doi:10.1016/0002-9343(90)90300-3

4. Barratt J, Feehally J. Semin Nephrol. 2011;31(4):349-360. doi:10.1016/j.semnephrol.2011.06.006

5. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int. 2012;2(suppl 2):259-274.

6. IgA Nephropathy Foundation of America, Inc. The Voice of the Patient: Externally Led Patient-Focused Drug Development Meeting on IgA Nephropathy. Accessed August 18, 2021.

7. Penfold RS, Prendecki M, McAdoo S, Tam FWK. Int J Nephrol Renovasc Dis. 2018;11:137-148. doi:10.2147/IJNRD.S129227

8. Arroyo AH, Bomback AS, Butler B, et al. Clin Nephrol. 2015;84(3):145-155. doi:10.5414/CN108556

9. Rauen T, Wied S, Fitzner C, et al; for the STOP-IgAN Investigators. Kidney Int Supp. 2020;98(4):1044-1052. doi:10.1016/j.kint.2020.04.046

10. Lafayette RA, Kelepouris E. Am J Nephrol. 2018;47(suppl 1):43-52. doi:10.1159/000481636

11. United States Renal Data System (USRDS). 2018 USRDS Annual Data Report. Vol 2. 2018; chap 9. Accessed April 7, 2021.

12. Golestaneh L, Alvarez PJ, Reaven N, et al. Am J Manag Care. 2017;23(10 Suppl):S163-S172.

13. Knoop T, Vikse BE, Svarstad E, Leh S, Reisæter AV, Bjørneklett R. Am J Kidney Dis. 2013;62(5):883-890. doi:10.1053/j.ajkd.2013.04.019

14. Ponticelli C, Glassock RJ. Clin J Am Soc Nephrol. 2010;5(12):2363-2372. doi:10.2215/CJN.06720810

15. Ponticelli C, Traversi L, Banfi G. Pediatr Transplant. 2004:8(4):334-338. doi:10.1111/j.1399-3046.2004.00177.x

16. Kiryluk K, Novak J. J Clin Invest. 2014;124(6):2325-2332. doi:10.1172/JCI74475

17. Yeo SC, Cheung CK, Barratt J. Pediatr Nephrol. 2018;33(5):763-777. doi:10.1007/s00467-017-3699-z

18. Jung C, Hugot JP, Barreau F. Int J Inflam. Published online September 19, 2010. doi:10.4061/2010/823710

19. Barratt J, Smith AC, Feehally J. Nephrology (Carlton). 2007;12(3):275-284. doi:10.1111/j.1440-1797.2007.00797.x

20. Boyd JK, Cheung CK, Molyneux K, Feehally J, Barratt J. Kidney Int. 2012;81(9):833-843. doi:10.1038/ki.2011.501

21. Lafayette RA. Transl Res. 2014;163(1):3-7. doi:10.1016/j.trasl.2013.08.007

22. Thompson A, Carroll K, Inker LA, et al. Clin J Am Soc Nephrol. 2019;14(3):469-481. doi:10.2215/CJN.08600718

23. Ibrahim A, Garg AX, Knoll GA, Akbari A, White CA. Am J Transplant. 2013;13(3):708-713. doi:10.1111/ajt.12050

24. Levey AS, Gansevoort RT, Coresh J, et al. Am J Kidney Dis. 2020;75(1):84-104. doi:10.1053/j.ajkd.2019.06.009

25. Goto M, Wakai K, Kawamura T, Ando M, Endoh M, Tomino Y. Nephrol Dial Transplant. 2009;24(10):3068-3074. doi:10.1093/ndt/gfp273

26. Brantsma AH, Atthobari J, Bakker SJ, de Zeeuw D, de Jong PE, Gansevoort RT. J Am Soc Nephrol. 2007;18(2):637-645. doi:10.1681/ASN.2006070738